{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:29:15Z","timestamp":1777393755244,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2015,12,14]]},"abstract":"<jats:p>Background: Benzodiazepines and related drugs (BZDR) are occasionally used to treat certain symptoms of Alzheimer\u2019s disease (AD). However, the risks related to BZDR use are high in older persons. Although frequent BZDR use has been reported in persons with AD, no previous study has focused specifically on the incidence of BZDR use in this population. Objective: We investigated the incidence of BZDR use in persons with and without AD during a five-year follow-up. Methods: The Finnish nationwide, register-based MEDALZ cohort includes all AD cases who received a clinically verified AD diagnosis in 2005\u20132011 (n\u200a=\u200a70,718) and their matched comparison persons. Incidence of BZDR, including benzodiazepines (lorazepam, oxazepam, temazepam, alprazolam, chlordiazepoxide, diazepam, and nitrazepam) and Z-drugs (zolpidem and zopiclone), use was investigated in the cohort from two years before to three years after the diagnosis of AD. Further, initial BZDRs were investigated. Results: The incidence of BZDR use was higher in persons with AD starting from 12 months before the diagnosis and peaked at six months after the diagnosis of AD (incidence rate ratio [IRR]\u200a=\u200a2.6, 95% confidence interval [CI]\u200a=\u200a2.5\u20132.8). Benzodiazepines were more frequently initiated by persons with AD, with the incidence peaking at six months after the diagnosis (IRR\u200a=\u200a4.5, 95% CI\u200a=\u200a4.1\u20134.9) and remaining over three times higher than in comparison persons until three years after the diagnosis. Conclusion: Early symptomatic treatment with BZDRs is contrary to AD treatment guidelines. As BZDRs impair cognition, the observed early treatment with BZDRs may complicate the monitoring of AD treatment effectiveness.<\/jats:p>","DOI":"10.3233\/jad-150630","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T08:44:50Z","timestamp":1450082690000},"page":"809-818","source":"Crossref","is-referenced-by-count":26,"title":["The Incidence of Benzodiazepine and\u00a0Related Drug Use in Persons with\u00a0and\u00a0without Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"49","author":[{"given":"Laura","family":"Saarelainen","sequence":"first","affiliation":[{"name":"Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland"},{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland"},{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"},{"name":"Research Centre for Comparative Effectiveness and Patient Safety, University of Eastern Finland, Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjaana","family":"Koponen","sequence":"additional","affiliation":[{"name":"Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland"},{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Impact Assessment Unit, National Institute for Health and Welfare, Helsinki, Finland"},{"name":"Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maija","family":"Tolppanen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"},{"name":"Research Centre for Comparative Effectiveness and Patient Safety, University of Eastern Finland, Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirpa","family":"Hartikainen","sequence":"additional","affiliation":[{"name":"Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland"},{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-150630_ref1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","article-title":"2015 Alzheimer\u2019s disease facts and figures","volume":"11","author":"Alzheimer\u2019s Association","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-150630_ref2","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"key":"10.3233\/JAD-150630_ref3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/gps.736","article-title":"A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer\u2019s disease","volume":"17","author":"Eustace","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-150630_ref5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2174\/138920011796504473","article-title":"Age-related changes in pharmacodynamics: Focus on drugs acting on central nervous and cardiovascular systems","volume":"12","author":"Trifir\u00f3","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.3233\/JAD-150630_ref6","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/gerona\/62.10.1172","article-title":"Medication as a risk factor for falls: Critical systematic review","volume":"62","author":"Hartikainen","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.3233\/JAD-150630_ref7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-014-1684-z","article-title":"Risk of hip fracture among older people using anxiolytic and hypnotic drugs: A nationwide prospective cohort study","volume":"70","author":"Bakken","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.3233\/JAD-150630_ref8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cger.2014.01.001","article-title":"Epidemiology of fragility fractures","volume":"30","author":"Friedman","year":"2014","journal-title":"Clin Geriatr Med"},{"key":"10.3233\/JAD-150630_ref9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/appi.ps.55.3.233","article-title":"Practical geriatrics:Use of benzodiazepines among elderly patients","volume":"55","author":"Bogunovic","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.3233\/JAD-150630_ref10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive effects of long-term benzodiazepine use: A meta-analysis","volume":"18","author":"Barker","year":"2004","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-150630_ref11","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer\u2019s disease: Case-control study","volume":"349","author":"de Gage","year":"2014","journal-title":"BMJ"},{"key":"10.3233\/JAD-150630_ref12","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.euroneuro.2014.10.004","article-title":"High prevalence of psychotropic drug use among persons with and without Alzheimer\u2019s disease in Finnish nationwide cohort","volume":"24","author":"Taipale","year":"2014","journal-title":"Eur Neuropsychopharm"},{"key":"10.3233\/JAD-150630_ref13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/YIC.0000000000000080","article-title":"Long-term use of benzodiazepines and related drugs among community-dwelling persons with and without Alzheimer\u2019s disease","volume":"30","author":"Taipale","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.3233\/JAD-150630_ref14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00228-013-1506-8","article-title":"Potentially inappropriate medication use among patients with Alzheimer disease in the REAL. FR cohort: Be aware of atropinic and benzodiazepine drugs!","volume":"69","author":"Montastruc","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.3233\/JAD-150630_ref15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/gps.3769","article-title":"The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer\u2019s disease","volume":"27","author":"Rosenberg","year":"2012","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-150630_ref16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jnnp.2006.104034","article-title":"The effects of commonly prescribed drugs in patients with Alzheimer\u2019s disease on the rate or deterioration","volume":"78","author":"Ellul","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-150630_ref17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/pds.853","article-title":"Benzodiazepine utilization patterns in Alzheimer\u2019s disease patients","volume":"12","author":"Lagnaoui","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.3233\/JAD-150630_ref18","first-page":"198","article-title":"Older adults with Alzheimer disease, comorbid arthritis and prescription of psychotropic medications","volume":"8","author":"Balfour","year":"2003","journal-title":"Pain"},{"key":"10.3233\/JAD-150630_ref19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/j.1875-9114.1995.tb04387.x","article-title":"Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer\u2019s disease","volume":"15","author":"Semla","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.3233\/JAD-150630_ref20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1176\/jnp.15.1.67","article-title":"Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer\u2019s disease from 1983 to 2000","volume":"15","author":"Lopez","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JAD-150630_ref21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1185\/030079905X65655","article-title":"Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer\u2019s disease","volume":"21","author":"Bartorelli","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.3233\/JAD-150630_ref22","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1111\/j.1532-5415.2011.03660.x","article-title":"Psychotropic medication burden and factors associated with antipsychotic use: An analysis of a population-based sample of community-dwelling older persons with dementia","volume":"59","author":"Rhee","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-150630_ref23","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS569>3.0.CO;2-J","article-title":"Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer\u2019s dementia","volume":"16","author":"Street","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-150630_ref24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2045125313508130","article-title":"The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer\u2019s disease with behavioral and psychological symptoms on dementia: A preliminary open-label trial","volume":"4","author":"Suzuki","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.3233\/JAD-150630_ref25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archneur.56.10.1266","article-title":"Psychiatric medication and abnormal behavioras predictors of progression in probable Alzheimer disease","volume":"56","author":"Lopez","year":"1999","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150630_ref26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1532-5415.1998.tb02540.x","article-title":"Newer psychotropic medication use in nursing home residents","volume":"46","author":"Lasser","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-150630_ref27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2147\/CLEP.S46622","article-title":"Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer\u2019s disease research\u2013the Medication use among persons with Alzheimer\u2019s disease (MEDALZ-2005) study","volume":"5","author":"Tolppanen","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.3233\/JAD-150630_ref28","unstructured":"Finnish Medical Society Duodecim 2010 The Finnish Medical Society Duodecim Memory Disorders. Current Care Guideline [in Finnish with English summary] Helsinki"},{"key":"10.3233\/JAD-150630_ref29","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV","author":"American Psychiatric Association","year":"1994"},{"key":"10.3233\/JAD-150630_ref30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.3233\/JAD-150630_ref31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jalz.2013.03.004","article-title":"Validity of dementia and Alzheimer\u2019s disease diagnoses in Finnish national registers","volume":"10","author":"Solomon","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-150630_ref33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1742-7843.2009.00494.x","article-title":"The Nordic countries as a cohort for pharmacoepidemiological research","volume":"106","author":"Furu","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.3233\/JAD-150630_ref34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/11315960-000000000-00000","article-title":"Validity of the Finnish prescription register for measuring psychotropic drug exposures among elderly Finns: A population-based intervention study","volume":"27","author":"Rikala","year":"2010","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-150630_ref35","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1186\/1756-0500-7-796","article-title":"From prescriptions to drug use periods - things to notice","volume":"7","author":"Tanskanen","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.3233\/JAD-150630_ref36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/mpr.1384","article-title":"Measuring psychotropic drug exposures in register-based studies - validity of a dosage assumption of one unit per day in older Finns","volume":"22","author":"Rikala","year":"2013","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.3233\/JAD-150630_ref37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods\u2013a second generation method (PRE2DUP)","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.3233\/JAD-150630_ref38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YIC.0000000000000032","article-title":"Antidementia drug use among community-dwelling individuals with Alzheimer\u2019s disease in Finland: A nationwide register-based study","volume":"29","author":"Taipale","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"10.3233\/JAD-150630_ref39","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1403494812456637","article-title":"Quality of the Finnish Hospital Discharge Register: A systematic review","volume":"40","author":"Sund","year":"2012","journal-title":"Scand J Public Health"},{"key":"10.3233\/JAD-150630_ref40","doi-asserted-by":"crossref","unstructured":"Defrancesco M Marksteiner J Fleischhacker WW Blasko I 2015 Use of benzodiazepines in Alzheimer\u2019s disease: A\u00a0systematic review of literature Int J Neuropsychopharmacol 18 10","DOI":"10.1093\/ijnp\/pyv055"},{"key":"10.3233\/JAD-150630_ref41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","article-title":"Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal","volume":"28","author":"Dell\u2019Osso","year":"2013","journal-title":"Eur Psychiatry"},{"key":"10.3233\/JAD-150630_ref42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2165\/00023210-200317110-00004","article-title":"Benzodiazepines and risk of hip fractures in older people: A review of the evidence","volume":"17","author":"Cumming","year":"2003","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-150630_ref43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/gps.3818","article-title":"Uncovering the source of new benzodiazepine prescriptions in community-dwelling older adults","volume":"28","author":"Halme","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-150630_ref44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1192\/bjp.bp.113.130948","article-title":"Behavioural and psychiatric symptoms inpeople with dementia admitted to the acute hospital: Prospective cohort study","volume":"205","author":"Sampson","year":"2014","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JAD-150630_ref45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/1471-2458-10-396","article-title":"Psychotropic drugs and the risk of fractures in old age: A prospective population-based study","volume":"10","author":"Nurminen","year":"2010","journal-title":"BMC Public Health"},{"key":"10.3233\/JAD-150630_ref46","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/bmj.322.7288.704","article-title":"Benzodiazepines and hip fractures in elderly people: Case-control study","volume":"322","author":"Pierfitte","year":"2001","journal-title":"BMJ"},{"key":"10.3233\/JAD-150630_ref47","doi-asserted-by":"crossref","first-page":"e5521","DOI":"10.1371\/journal.pone.0005521","article-title":"Incidence and prediction of falls in dementia: A prospective study in older people","volume":"4","author":"Allan","year":"2009","journal-title":"PLoS One"},{"key":"10.3233\/JAD-150630_ref48","doi-asserted-by":"crossref","first-page":"e59124","DOI":"10.1371\/journal.pone.0059124","article-title":"Incident hip fractures among community dwelling persons with Alzheimer\u2019s disease in a Finnish nationwide register-based cohort","volume":"8","author":"Tolppanen","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-150630_ref49","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/JGP.0b013e3181d6b68d","article-title":"Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease","volume":"18","author":"Spalletta","year":"2010","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-150630_ref50","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence","volume":"293","author":"Sink","year":"2005","journal-title":"JAMA"},{"key":"10.3233\/JAD-150630_ref51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","article-title":"Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-150630_ref52","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1111\/j.1365-2125.1981.tb01833.x","article-title":"Benzodiazepines: A summary of pharmacokinetic properties","volume":"11","author":"Greenblatt","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JAD-150630_ref53","doi-asserted-by":"crossref","unstructured":"McCleery J 2014 Cochrane Database of Systematic Reviews Pharmacotherapies for sleep disturbances in Alzheimer\u2019s disease John Wiley & Sons, Ltd","DOI":"10.1002\/14651858.CD009178.pub2"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-150630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:01:32Z","timestamp":1777370492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-150630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":51,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-150630","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,14]]}}}